Search Results
Search for other papers by Kristen Wong in
Google Scholar
PubMed
Search for other papers by Francesca Di Cristofano in
Google Scholar
PubMed
Search for other papers by Michela Ranieri in
Google Scholar
PubMed
Search for other papers by Daniela De Martino in
Google Scholar
PubMed
Search for other papers by Antonio Di Cristofano in
Google Scholar
PubMed
. Drug treatments and cell proliferation assay The CDK4/6 inhibitor palbociclib was provided by Pfizer and prepared in 50 mM lactate. The PI3K/mTOR inhibitor, omipalisib, and the MEK inhibitor, trametinib, were purchased from Selleck Chemicals (Houston
Search for other papers by Rhonda L Bitting in
Google Scholar
PubMed
Search for other papers by Andrew J Armstrong in
Google Scholar
PubMed
with metastatic CRPC, the survival rate of patients with metastatic CRPC remains poor and additional therapeutic approaches are needed. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key oncogenic
Search for other papers by Lidong Wang in
Google Scholar
PubMed
Search for other papers by Hao Tan in
Google Scholar
PubMed
Search for other papers by Yonglian Huang in
Google Scholar
PubMed
Search for other papers by Mingyue Guo in
Google Scholar
PubMed
Search for other papers by Yanxu Dong in
Google Scholar
PubMed
Search for other papers by Chenxi Liu in
Google Scholar
PubMed
Search for other papers by Huai Zhao in
Google Scholar
PubMed
Search for other papers by Zhen Liu in
Google Scholar
PubMed
( Table 2 ). Table 2 Primary antibodies used in this study. Proteins Primary antibodies Details TAGLN2 Rabbit polyclonal anti-TAGLN2 antibody 1:1000, 10234-2-AP, Proteintech t-PI3K Mouse monoclonal anti-PI3K p85
Search for other papers by Shahab Uddin in
Google Scholar
PubMed
Search for other papers by Prashant Bavi in
Google Scholar
PubMed
Search for other papers by Abdul K Siraj in
Google Scholar
PubMed
Search for other papers by Maqbool Ahmed in
Google Scholar
PubMed
Search for other papers by Maha Al-Rasheed in
Google Scholar
PubMed
Search for other papers by Azhar R Hussain in
Google Scholar
PubMed
Search for other papers by Mohammed Ahmed in
Google Scholar
PubMed
Search for other papers by Tarek Amin in
Google Scholar
PubMed
Search for other papers by Ali Alzahrani in
Google Scholar
PubMed
Search for other papers by Fouad Al-Dayel in
Google Scholar
PubMed
Search for other papers by Jehad Abubaker in
Google Scholar
PubMed
Search for other papers by Rong Bu in
Google Scholar
PubMed
Search for other papers by Khawla S Al-Kuraya in
Google Scholar
PubMed
transduced by Janus activated kinase/signal transducers and activators of transcription (JAK/STAT), mitogen-activated protein kinase (MAPK), and phosphatidylinisitol-3′-kinase (PI3K) signaling pathways ( Hegyi et al . 2004 ). Previously, we have shown that
Search for other papers by Misu Lee in
Google Scholar
PubMed
Search for other papers by Ninelia Minaskan in
Google Scholar
PubMed
Search for other papers by Tobias Wiedemann in
Google Scholar
PubMed
Search for other papers by Martin Irmler in
Google Scholar
PubMed
German Center for Diabetes Research (DZD), Neuherberg, Germany
Technische Universität München, Chair of Experimental Genetics, Freising, Germany
Search for other papers by Johannes Beckers in
Google Scholar
PubMed
Search for other papers by Behrooz H Yousefi in
Google Scholar
PubMed
Search for other papers by Georgios Kaissis in
Google Scholar
PubMed
Search for other papers by Rickmer Braren in
Google Scholar
PubMed
Search for other papers by Iina Laitinen in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
( Eisenhofer et al. 2011 ). Activation of the PI3K/AKT/mTOR pathway plays a pivotal role in the initiation and progression of many human malignancies by enhancing cell survival, stimulating cell proliferation and inhibiting apoptosis ( Cantrell 2001
Search for other papers by Meng Ji in
Google Scholar
PubMed
University of the Chinese Academy of Sciences, Beijing, China
Search for other papers by Yanli Yao in
Google Scholar
PubMed
Search for other papers by Anan Liu in
Google Scholar
PubMed
Search for other papers by Ligang Shi in
Google Scholar
PubMed
Search for other papers by Danlei Chen in
Google Scholar
PubMed
Search for other papers by Liang Tang in
Google Scholar
PubMed
Search for other papers by Guang Yang in
Google Scholar
PubMed
Search for other papers by Xing Liang in
Google Scholar
PubMed
Search for other papers by Junfeng Peng in
Google Scholar
PubMed
Search for other papers by Chenghao Shao in
Google Scholar
PubMed
overexpressed in pNEN tissues and was positively correlated with H19 expression to promote cancer progression. Moreover, higher VGF expression was markedly related to poor differentiation and advanced stage. RNA sequence analysis revealed that H19 activates PI3K
Search for other papers by Teresa Gagliano in
Google Scholar
PubMed
Search for other papers by Mariaenrica Bellio in
Google Scholar
PubMed
Section of Endocrinology, Laboratorio in Rete del Tecnopolo ‘Tecnologie delle Terapie Avanzate’ (LTTA), Department of Cardiological, Department of Morphology, Department of Medical Sciences, University of Ferrara, Via Savonarola 9, 44121 Ferrara, Italy
Search for other papers by Erica Gentilin in
Google Scholar
PubMed
Search for other papers by Daniela Molè in
Google Scholar
PubMed
Search for other papers by Federico Tagliati in
Google Scholar
PubMed
Search for other papers by Marco Schiavon in
Google Scholar
PubMed
Search for other papers by Narciso Giorgio Cavallesco in
Google Scholar
PubMed
Search for other papers by Luigi Gaetano Andriolo in
Google Scholar
PubMed
Search for other papers by Maria Rosaria Ambrosio in
Google Scholar
PubMed
Search for other papers by Federico Rea in
Google Scholar
PubMed
Section of Endocrinology, Laboratorio in Rete del Tecnopolo ‘Tecnologie delle Terapie Avanzate’ (LTTA), Department of Cardiological, Department of Morphology, Department of Medical Sciences, University of Ferrara, Via Savonarola 9, 44121 Ferrara, Italy
Search for other papers by Ettore degli Uberti in
Google Scholar
PubMed
Section of Endocrinology, Laboratorio in Rete del Tecnopolo ‘Tecnologie delle Terapie Avanzate’ (LTTA), Department of Cardiological, Department of Morphology, Department of Medical Sciences, University of Ferrara, Via Savonarola 9, 44121 Ferrara, Italy
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
-BEZ235. The latter is an imidazo (4,5-c)quinoline derivative that inhibits both phosphatidylinositol 3-kinase (PI3K) and mTOR activities, inducing G1 arrest in cell-cycle progression ( Maira et al . 2008 ). It has been demonstrated previously that NVP
Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK
Search for other papers by S C Drury in
Google Scholar
PubMed
Search for other papers by S Detre in
Google Scholar
PubMed
Search for other papers by A Leary in
Google Scholar
PubMed
Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK
Search for other papers by J Salter in
Google Scholar
PubMed
Search for other papers by J Reis-Filho in
Google Scholar
PubMed
Search for other papers by V Barbashina in
Google Scholar
PubMed
Search for other papers by C Marchio in
Google Scholar
PubMed
Search for other papers by E Lopez-Knowles in
Google Scholar
PubMed
Search for other papers by Z Ghazoui in
Google Scholar
PubMed
Search for other papers by K Habben in
Google Scholar
PubMed
Search for other papers by S Arbogast in
Google Scholar
PubMed
Search for other papers by S Johnston in
Google Scholar
PubMed
Translational Research, Academic Biochemistry, Royal Marsden Hospital, Molecular Pathology, Department of Biomedical Sciences and Human Oncology, Roche Diagnostics GmbH, Breast Unit, The Breakthrough Breast Cancer Research Centre, London, UK
Search for other papers by M Dowsett in
Google Scholar
PubMed
-IGF1R phosphorylating IRS1, IRS2 and Shc, activating transduction pathways such as PI3K and Ras/Raf/MAPK ( Riedemann & Macaulay 2006 ). In addition, IGF1R physically associates with ERα and this leads to activation of IGF1R and the downstream ERK1
Barts and the London School of Medicine, Department of Endocrinology and Internal Medicine, Division of Endocrinology and Metabolism, Internal Medicine, Institute of Endocrinology and Metabolism, Centre for Endocrinology, London, UK
Search for other papers by D Dworakowska in
Google Scholar
PubMed
Search for other papers by E Wlodek in
Google Scholar
PubMed
Search for other papers by C A Leontiou in
Google Scholar
PubMed
Search for other papers by S Igreja in
Google Scholar
PubMed
Barts and the London School of Medicine, Department of Endocrinology and Internal Medicine, Division of Endocrinology and Metabolism, Internal Medicine, Institute of Endocrinology and Metabolism, Centre for Endocrinology, London, UK
Search for other papers by M Cakir in
Google Scholar
PubMed
Search for other papers by M Teng in
Google Scholar
PubMed
Search for other papers by N Prodromou in
Google Scholar
PubMed
Search for other papers by M I Góth in
Google Scholar
PubMed
Barts and the London School of Medicine, Department of Endocrinology and Internal Medicine, Division of Endocrinology and Metabolism, Internal Medicine, Institute of Endocrinology and Metabolism, Centre for Endocrinology, London, UK
Search for other papers by S Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by M Gueorguiev in
Google Scholar
PubMed
Search for other papers by B Kola in
Google Scholar
PubMed
Search for other papers by M Korbonits in
Google Scholar
PubMed
Search for other papers by A B Grossman in
Google Scholar
PubMed
identified ( Dworakowska & Grossman 2009 b ). Two major signalling pathways responsible for regulating cell growth and proliferation, downstream of growth factor receptors, are the phosphatidylinositol 3-kinase (PI3K)/Akt and Raf/mitogen-activated protein
Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, Germany
Search for other papers by Ajay-Mohan Mohan in
Google Scholar
PubMed
Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, Germany
Search for other papers by Sonal Prasad in
Google Scholar
PubMed
Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, Germany
Search for other papers by Fabian Schmitz-Peiffer in
Google Scholar
PubMed
Search for other papers by Catharina Lange in
Google Scholar
PubMed
Search for other papers by Mathias Lukas in
Google Scholar
PubMed
German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany
Search for other papers by Eva J Koziolek in
Google Scholar
PubMed
Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, Germany
German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany
Search for other papers by Jakob Albrecht in
Google Scholar
PubMed
Preclinical MRI Center, Charité - Universitätsmedizin Berlin, Berlin, Germany
Search for other papers by Daniel Messroghli in
Google Scholar
PubMed
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Translational Oncology of Solid Tumours, Berlin, Germany
Search for other papers by Ulrike Stein in
Google Scholar
PubMed
Department of General, Visceral, and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany
German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Matthias Ilmer in
Google Scholar
PubMed
Search for other papers by Katharina Wang in
Google Scholar
PubMed
Search for other papers by Laura Schober in
Google Scholar
PubMed
Search for other papers by Astrid Reul in
Google Scholar
PubMed
Search for other papers by Julian Maurer in
Google Scholar
PubMed
Search for other papers by Juliane Friemel in
Google Scholar
PubMed
Search for other papers by Achim Weber in
Google Scholar
PubMed
Search for other papers by Richard A Zuellig in
Google Scholar
PubMed
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital, University of Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
Search for other papers by Constanze Hantel in
Google Scholar
PubMed
Search for other papers by Ralph Fritsch in
Google Scholar
PubMed
Search for other papers by Martin Reincke in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, United Kingdom
ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich, Munich, Germany
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, Germany
German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany
Search for other papers by Winfried Brenner in
Google Scholar
PubMed
Search for other papers by Nicola Beindorff in
Google Scholar
PubMed
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital, University of Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
Search for other papers by Svenja Nölting in
Google Scholar
PubMed
everolimus there is increased activation of glycogen synthase kinase3 (GSK3, an effector protein in the PI3K-Akt signalling pathway) in combination with decreased baseline insulin receptor substrate-1 (IRS-1) protein levels, G1 cell cycle arrest, and